Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.68 |
| ▸ | HTR2C | P28335 | 17/20 | 0.68 |
| ▸ | HTR2B | P41595 | 8/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.68 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905933 | 1.00 | HTR2A (0.68) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL8006854 | 0.89 | HTR2A (0.58) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL8009273 | 0.89 | HTR2A (0.58) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL8009278 | 0.89 | HTR2A (0.58) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL906040 | 0.85 | HTR2A (0.60) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL15713263 | 0.83 | HTR2A (0.47) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL10252671 | 0.82 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL8007544 | 0.81 | HTR2C (0.69) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL4779282 | 0.81 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL6088764 | 0.81 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | ASTELLAS PHARMA INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2400300-A1 | Method of screening preventives/remedies for stress urinary incontinence | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011071136-A1 | THERAPEUTIC AGENT FOR FIBROMYALGIA | アステラス製薬株式会社 (JP) | 2011-06-16 | — | — | WO | disclosed |
| EP-2248524-A2 | Preventives/remedies for stress urinary incontinence and method of screening the same | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1792629-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | ADRA2C, HTR2C, HTR3A | HTR2A 5/4885HTR2C 2/4885HTR2B 15/4885 |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2A 4/4885HTR2C 1/4885HTR2B 5/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | HTR2A 4/4885HTR2C 1/4885HTR2B 5/4885 |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | HTR2A, HTR2C, HTR3A | HTR2A 1/4885HTR2C 2/4885HTR2B 4/4885 |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | HTR2A 9/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | ADRA2C, HTR2C, HTR3A | HTR2A 5/4885HTR2C 2/4885HTR2B 15/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2A 4/4885HTR2C 1/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.